Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · IEX Real-Time Price · USD
962.49
-3.81 (-0.39%)
At close: Mar 28, 2024, 4:00 PM
962.45
-0.04 (0.00%)
After-hours: Mar 28, 2024, 7:26 PM EDT

Company Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.

The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals logo
Country United States
Founded 1988
IPO Date Apr 2, 1991
Industry Biotechnology
Sector Healthcare
Employees 13,450
CEO Dr. Leonard S. Schleifer M.D., Ph.D.

Contact Details

Address:
777 Old Saw Mill River Road
Tarrytown, New York 10591
United States
Phone (914) 847-7000
Website regeneron.com

Stock Details

Ticker Symbol REGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000872589
CUSIP Number 75886F107
ISIN Number US75886F1075
Employer ID 13-3444607
SIC Code 2834

Key Executives

Name Position
Dr. Leonard S. Schleifer M.D., Ph.D. Co-Founder, President, Chief Executive Officer and Co-Chairman
Dr. George D. Yancopoulos M.D., Ph.D. Co-Founder, President, Chief Scientific Officer and Co-Chairman
Dr. Andrew J. Murphy Ph.D. Executive Vice President of Research
Daniel P. Van Plew Executive Vice President and GM of Industrial Operations and Product Supply
Marion E. McCourt Executive Vice President of Commercial
Christopher R. Fenimore CPA Senior Vice President of Finance and Chief Financial Officer
Patrice Gilooly Senior Vice President of Quality Assurance and Operations
Bob McCowan Senior Vice President of IT and Chief Information Officer
Ryan Crowe Senior Vice President of Investor Relations and Strategic Analysis
Joseph J. LaRosa Executive Vice President, General Counsel and Secretary

Latest SEC Filings

Date Type Title
Mar 14, 2024 144 Filing
Mar 1, 2024 144 Filing
Feb 26, 2024 144 Filing
Feb 26, 2024 144 Filing
Feb 26, 2024 144 Filing
Feb 23, 2024 144 Filing
Feb 22, 2024 144 Filing
Feb 22, 2024 144 Filing
Feb 14, 2024 144 Filing
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals